Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesTSXV:ZYUS 16 EBITDA Margin % is -1,781.97% as of Mar. 2026. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 98.54% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ZYUS Life Sciences's EBITDA for the
three
months ended in Mar. 2026 was C$-2.17 Mil. ZYUS Life Sciences's Revenue for the
three
months ended in Mar. 2026 was C$0.12 Mil. Therefore, ZYUS Life Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was -1,781.97%.
ZYUS Life Sciences (TSXV:ZYUS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ZYUS Life Sciences EBITDA Margin % Related Terms
ZYUS Life Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ZYUS Life Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:ZYUS vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (TSXV:ZYUS) has a EBITDA Margin % of -1,781.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #945 out of 959 companies in the Drug Manufacturers industry, placing it in the top 98.5%.
Is ZYUS Life Sciences' EBITDA Margin % too high?
ZYUS Life Sciences' current EBITDA Margin % is -1,781.97%. Based on the distribution chart, ZYUS Life Sciences ranks #945 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #945 out of 959 companies for EBITDA Margin %. This places ZYUS Life Sciences in the lower half of its industry. The industry median EBITDA Margin % is 12.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ZYUS Life Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current EBITDA Margin % is -1,781.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current EBITDA Margin % of -1,781.97%. The current EBITDA Margin % is -1,781.97%. ZYUS Life Sciences' overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current EBITDA Margin % is -1,781.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score
Get the complete analysis for TSXV:ZYUS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZYUS has been successfully added to your 
